Notes And Other Explanatory Information [Abstract]

Pharming Group N.V. - Filing #1883078

Concept	2022-01-01 to 2022-12-31
Notes and other explanatory information [abstract]
Disclosure of accounting judgements and estimates [text block]	Critical accounting judgements and key sources of estimation uncertainty
Disclosure of allowance for credit losses [text block]	The Company did not recognize any expected credit losses. Pharming measures the loss allowance for trade receivables at an amount equal to lifetime ECL. The expected credit losses on trade receivables are estimated using a provision
Disclosure of auditors' remuneration [text block]	Independent auditor’s fees
Disclosure of authorisation of financial statements [text block]	Date of authorization of issue
Disclosure of basis of preparation of financial statements [text block]	Basis of preparation
Disclosure of borrowings [text block]	Convertible bo
Disclosure of commitments [text block]	Commitments and contingencies
Disclosure of cost of sales [text block]	Costs of sales
Disclosure of credit risk [text block]	Credit risk
Disclosure of debt instruments [text block]	1
Disclosure of deferred taxes [text block]	Deferred tax
Disclosure of depreciation and amortisation expense [text block]	Depreciation and amortization charges
Disclosure of earnings per share [text block]	Earnings per share and diluted shares
Disclosure of effect of changes in foreign exchange rates [text block]	Currency risk
Disclosure of employee benefits [text block]	Employee benefits
Disclosure of entity's operating segments [text block]	Segment information
Disclosure of events after reporting period [text block]	Events after the reporting period
Disclosure of expenses by nature [text block]	Expenses by nature
Disclosure of fair value measurement [text block]	Fair value estimation
Disclosure of finance income [text block]	O
Disclosure of financial instruments [text block]	Restricted cash, cash and cash equivalents
Disclosure of financial risk management [text block]	Fin
Disclosure of first-time adoption [text block]	The Company applied for the first-time certain amendments, which are effective for annual periods beginning on or after
Disclosure of general and administrative expense [text block]	Costs of general and administrative activities
Disclosure of general information about financial statements [text block]	Cor
Disclosure of going concern [text block]	Go
Disclosure of income tax [text block]	Income tax
Disclosure of information about employees [text block]	The number of employees
Disclosure of information about key management personnel [text block]	Boar
Disclosure of intangible assets and goodwill [text block]	I
Disclosure of interests in other entities [text block]	Investments
Disclosure of inventories [text block]	Inventories
Disclosure of investments accounted for using equity method [text block]	13.1 Investments accounted for using the equity method
Disclosure of issued capital [text block]	The Company’s authorized share capital amounts to
Disclosure of leases [text block]	Right-of-use assets
Disclosure of liquidity risk [text block]	Liquidity risk
Disclosure of other liabilities [text block]	Other financial
Disclosure of other operating income [text block]	Other
Disclosure of prepayments and other assets [text block]	Trade and
Disclosure of property, plant and equipment [text block]	Property, plant and equipment
Disclosure of related party [text block]	Related party transactions
Disclosure of research and development expense [text block]	Costs of research and development
Disclosure of reserves within equity [text block]	Other
Disclosure of revenue from contracts with customers [text block]	Revenues
Disclosure of share-based payment arrangements [text block]	Share-based compensation
Disclosure of subsidiaries [text block]	The following table provides an overview of the consolidated subsidiaries at
Disclosure of trade and other payables [text block]	Trade and